Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
365 Results for "
glp-1
" in MedChemExpress (MCE) Product Catalog:
Products (365)
365 Results for "glp-1" in MCE Product Catalog:
45
Target:
Research Areas:
45
Target:
Research Areas:
45
45 Publications Verification
Research Areas:
45
45 Publications Verification
Research Areas:
45
45 Publications Verification
Cat. No.: HY-114118A
Purity: 99.92%
Research Areas:
42
42 Cited Publications
Cat. No.: HY-P0014B
Target:
Research Areas:
42
42 Cited Publications
Cat. No.: HY-P0014
CAS No.: 204656-20-2
Target:
Research Areas:
31
Target:
Research Areas:
Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Sitagliptin (MK-0431) is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes [1] .
31
31 Cited Publications
Synonyms: MK-0431 phosphate
Target:
Research Areas:
Sitagliptin (MK-0431) phosphate is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin phosphate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate can be used for the study of 1-type and 2-type diabetes [1] .
31
31 Cited Publications
Synonyms: MK-0431 phosphate monohydrate
Target:
Research Areas:
Sitagliptin (MK-0431) phosphate monohydrate is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin phosphate monohydrate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate monohydrate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate monohydrate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate monohydrate can be used for the study of 1-type and 2-type diabetes [1] .
10
10 Cited Publications
Cat. No.: HY-P0054A
CAS No.: 107444-51-9
Synonyms: Glucagon-like peptide-1 (glp-1)(7-36), amide; Human glp-1 (7-36), amide
Target:
Research Areas:
10
10 Cited Publications
Cat. No.: HY-P0054
CAS No.: 1119517-19-9
Synonyms: Glucagon-like peptide-1 (glp-1)(7-36), amide acetate; Human glp-1 (7-36), amide acetate
Target:
Research Areas:
10
10 Cited Publications
Cat. No.: HY-P0054B
Synonyms: Glucagon-like peptide-1 (glp-1)(7-36), amide TFA; Human glp-1 (7-36), amide TFA
Target:
Research Areas:
10
10 Cited Publications
Cat. No.: HY-P0055
CAS No.: 106612-94-6
Target:
Research Areas:
10
10 Cited Publications
Cat. No.: HY-P0055A
CAS No.: 1450806-98-0
Target:
Research Areas:
7
7 Cited Publications
Target:
Research Areas:
GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM [1].
4
Target:
Research Areas:
Danuglipron (PF-06882961) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron has the potential for type 2 diabetes research [1] .
3
3 Cited Publications
Cat. No.: HY-P0119
CAS No.: 320367-13-3
3
3 Cited Publications
Cat. No.: HY-P0119A
CAS No.: 1997361-87-1
3
Target:
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
